Clinical trials: Coagulopathy
Immune Thrombocytopenia
Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)
This is a phase 3b single arm, open label, multicenter study describing the percentage of time pediatric participants with ITP have a platelet response while receiving romiplostim, defined as a platelet count ≥ 50 x 10^9/L in the…
- Trial name
- NCT02279173
- Testing
- Romiplostim
- Where
- 78 sites in United States, Australia and 15 more
- Volunteers
- 203 people
- Sponsor
- Amgen
Myeloproliferative Neoplasms (MPNs)
A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms
This is a multi-center, open-label, Phase 1/1b study designed to evaluate the safety, pharmacokinetics, immunogenicity, and preliminary efficacy of DMR-001 monotherapy in adult participants with CALR-mutated essential…
- Trial name
- CLARITY-101 (NCT07849231)
- Testing
- DMR-001, Ruxolitinib
- Where
- 36 sites in United States, Australia
- Volunteers
- 250 people
- Sponsor
- Damora Therapeutics
Primary Immune Thrombocytopenia (ITP)
A PHASE II TRIAL AIMING TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA PREVIOUSLY TREATED WITH A THROMBOPOIETIN RECEPTOR AGONIST AND/OR RITUXIMAB AFTER CORTICOSTEROID FIRST-LINE THERAPY
This is a Phase II open label, prospective, multicenter trial designed to assess the safety and clinical activity of belantamab mafodotin in adult patients with primary immune thrombocytopenia (ITP) previously treated with a…
- Trial name
- BONSAI (NCT07019545)
- Testing
- Belantamab Mafodotin, Dexamethasone
- Where
- Greece
- Volunteers
- 14 people
- Sponsor
- Hellenic Society of Hematology
Hemophilia A With Inhibitor, Hemophilia B With Inhibitor
SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors
Phase IV multi-center, US-centric, open-label, safety study enrolling participants with Hemophilia A or B with inhibitors, 12 years of age and older, who are either on long term prophylactic treatment (e.g., emicizumab) at risk…
- Trial name
- NCT04647227
- Testing
- coagulation factor VIIa [recombinant]-jncw
- Where
- 21 sites in United States
- Volunteers
- 55 people
- Sponsor
- American Thrombosis and Hemostasis Network
Immune Thrombocytopenic Purpura
Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP
This study is designed to compare the efficacy and safety of higher doses of Rituxan with a regimen combining standard doses of Rituxan + CVP in patients with chronic ITP who did not respond to or relapsed after standard doses of…
- Trial name
- NCT00774202
- Testing
- Rituxan, Cyclophosphamide, Vincristine, Prednisone, Higher Dose of Rituximab
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Weill Medical College of Cornell University
Hemophilia
Global Haemostatic Methods Following Administration of Bypassing Agents to Patients With Haemophilia With Inhibitors
Background The treatment of haemophilia A and B has been revolutionized by the use of factor concentrate, both as prophylaxis and to treat bleeding episodes (on-demand treatment).
- Trial name
- NCT02453542
- Where
- Sweden
- Volunteers
- 20 people
- Sponsor
- Karolinska Institutet
Hemophilia Arthropathy
Pain in Patients With Congenital Coagulopathies
Introduction. The development of joint hemorrhages in patients with congenital coagulopathies favor the development of an intra-articular, degenerative and progressive lesion (hemophilic arthropathy).
- Trial name
- He-PainSit (NCT03499522)
- Testing
- Observational group
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Real Fundación Victoria Eugenia
Health Services Accessibility, Blood Coagulation Factor Deficiencies
Accessibility of Prophylaxis and On-demand Treatment for Persons With Haemophilia and Other Coagulation Deficiencies
The current treatment of people with haemophilia and other bleeding deficiencies is largely based on clotting factor replacement therapy. The injections can be repeated several times a week according to a personalized schedule.
- Trial name
- PHAREO (NCT04775888)
- Where
- 34 sites in France
- Volunteers
- 500 people
- Sponsor
- RESCUe - RESeau Cardiologie Urgence / RESUVal - RESeau des Urgences de la vallée du Rhône
Hemophilia B
A Long-Term Follow-Up Study of Haemophilia B Patients Who Have Undergone Gene Therapy
Severe haemophilia B (HB) is a bleeding disorder where a protein made by the body to help make blood clot is either partly or completely missing.
- Trial name
- NCT03641703
- Testing
- FLT180a
- Where
- 6 sites in United Kingdom
- Volunteers
- 10 people
- Sponsor
- Spur Therapeutics
ITP - Immune Thrombocytopenia
Exploring the Efficacy, Safety of a Modified Starting Dosage of Avatrombopag in Immune Throbocytopenia (ITP) - a Pilot Study
This is a single-center, open label pilot trial where patients with primary ITP who require second line treatment will be offered avatrombopag at a reduced starting dose, adjusted thereafter according to the response and…
- Trial name
- Ava dosing (NCT07133659)
- Testing
- Avatrombopag 20 mg Oral Tablet
- Where
- Iraq
- Volunteers
- 25 people
- Sponsor
- Al-Mustansiriyah University
Thrombocythemia Essential
Prospective Study of Different Biological Tests (Multiplate, ROTEM) in a Cohort of Patients Followed for Essential Thrombocytemia (ET)
There is no prospective study published on the Essential Thrombocythemia and the correlation between this specific disease, its complications and the biological variations observed.
- Trial name
- THETE (NCT03212053)
- Testing
- biological tests of haemostasis at each consultation (Multiplate, ROTEM, VASP)
- Where
- France
- Volunteers
- 51 people
- Sponsor
- Hospices Civils de Lyon
Hemophilia A
Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients
The purpose of this study is to evaluate whether Antihemophilic factor, recombinant, manufactured protein-free (rAHF-PFM) is effective and safe in the treatment of hemophilia A patients who have not been treated with factor VIII…
- Trial name
- NCT00157157
- Testing
- Recombinant Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)
- Where
- 35 sites in United States, Austria and 8 more
- Volunteers
- 66 people
- Sponsor
- Baxalta now part of Shire
Bleeding Disorder
Screening for Bleeding Disorders in Children
The investigators try to improve the screening of bleeding disorders in children by identifying symptoms, laboratory abnormalities and clinical scores discriminating patients congenital bleeding disorders in order to create a…
- Trial name
- NCT05214300
- Where
- France
- Volunteers
- 96 people
- Sponsor
- University Hospital, Montpellier
Traumatic Brain Injury, Coagulation Disorder
The Relationship Between Lipid Peroxidation Products From Traumatic Brain Injury and Secondary Coagulation Disorders
The purpose of this study is to observe the relationship between the level of lipid peroxidation products in serum of patients with traumatic brain injury and secondary coagulation disorders.
- Trial name
- NCT04274777
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Tang-Du Hospital
Hemophilia
First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients
The purpose of this study is to examine the safety, tolerability and the way the body handles various single and multiple doses of ARC19499 in patients with hemophilia.
- Trial name
- NCT01191372
- Testing
- ARC19499
- Where
- United Kingdom
- Volunteers
- 17 people
- Sponsor
- Baxalta now part of Shire
Idiopathic Thrombocytopenic Purpura, Immune Thrombocytopenia
Lusutrombopag in the Treatment of Immune Thrombocytopenia (ITP)
This exploratory study is to investigate the efficacy, safety and tolerability of Lusutrombopag in the treatment of primary immune thrombocytopenia in Chinese patients who have failed first-line therapy
- Trial name
- NCT06287567
- Testing
- Lusutrombopag Oral Tablet
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Chronic Myeloproliferative Disorders, Leukemia
Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and busulfan, before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- Bu Flu TBI (NCT00245037)
- Testing
- therapeutic allogeneic lymphocytes, busulfan, cyclosporine
- Where
- United States
- Volunteers
- 147 people
- Sponsor
- OHSU Knight Cancer Institute
Chronic Leukemia, Acute Leukemia
Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic Diseases
In this study, patients will receive a myeloablative preparative regimen consisting of fludarabine and total body irradiation (TBI), followed by a T cell replete, mobilized peripheral blood stem cell (PBSC) allograft from a…
- Conditions
- Chronic Leukemia, Acute Leukemia, Hodgkin's Disease, Non-Hodgkin's Lymphoma
- Trial name
- NCT01336712
- Testing
- Peripheral Blood Stem Cell Transplant
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Northside Hospital, Inc.
Hemophilia, Arthropathy
Observational Study of Long-Term Joint Health Outcome in Hemophilia Patient
Patients with severe hemophilia A can experience repeated bleeding into the same joint (ie, a target joint; most frequently in the ankle, knee, and elbow), which can contribute to hemophilic arthropathy and, over time, ultimately…
- Trial name
- NCT04618237
- Where
- Taiwan
- Volunteers
- 35 people
- Sponsor
- Taipei Medical University Hospital
Hemophilia A
Health-Related Quality of Life Outcomes and Bleeding Rates Among Patients With Severe Hemophilia A on Emicizumab
The main purposes of this study are to determine if use of emicizumab prophylaxis treatment reduces number of bleeding episodes, if it improves quality of life of individuals and if improves arthropathy in persons with hemophilia…
- Trial name
- ML43518 (NCT06104826)
- Testing
- Emicizumab
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Newark Beth Israel Medical Center